The global vaccine industry is entering a different phase in 2026.

COVID-19 vaccination is moving toward more targeted seasonal protection. Mpox has become a long-term preparedness issue rather than a short-lived outbreak story. At the same time, measles is returning in countries where routine childhood immunization has weakened.

The result is a vaccine landscape shaped by three competing priorities: maintaining routine immunization, responding rapidly to outbreaks, and developing vaccines for emerging infectious diseases.

For pharmaceutical companies, governments, investors and vaccine developers, the opportunity is no longer limited to developing another vaccine. The bigger question is whether the industry can build faster manufacturing, reliable supply chains, broader protection, flexible platforms and stronger vaccination programs before the next public-health emergency arrives.

Global Vaccine Trends in 2026 at a Glance

Trend	What is changing in 2026	Strategic implication
COVID-19	Vaccines are being updated for circulating variants	Faster strain-selection and manufacturing cycles
Mpox	Long-term stockpiling and outbreak preparedness are increasing	Strategic vaccine reserves and manufacturing capacity
Measles	Outbreaks are exposing immunization gaps	Stronger routine vaccination infrastructure
mRNA	Platforms are expanding beyond COVID-19	Faster vaccine development potential
Next-generation vaccines	RSV, TB, chikungunya and other targets are advancing	New commercial opportunities
Global access	Zero-dose and under-immunized populations remain a major challenge	Procurement, pricing and distribution intelligence

The global vaccine opportunity is therefore becoming more diversified. COVID-19 remains commercially important, but the industry’s next growth areas increasingly include RSV, shingles, pneumococcal disease, HPV, malaria, TB, mpox, chikungunya and other emerging or re-emerging infectious diseases.

The global vaccines market size is calculated at USD 84.97 billion in 2025, grew to USD 88.40 billion in 2026, and is projected to reach around USD 126.26 billion by 2035. The market is expanding at a CAGR of 4.04% between 2025 and 2035.

Download Sample : https://www.towardshealthcare.com/download-sample/6008

COVID-19 Vaccines Are Entering a More Targeted Phase

COVID-19 has moved from emergency vaccination toward a more targeted immunization model.

In the United States, the FDA recommended that the 2026–2027 COVID-19 vaccine formula use the JN.1-lineage XFG variant as the preferred target.

By August 2026, the FDA had approved updated COVID-19 vaccines from Moderna, Pfizer-BioNTech and Novavax-Sanofi for the 2026–2027 season.

This is commercially important because COVID-19 vaccine development is increasingly becoming an exercise in:

• Variant surveillance
• Strain selection
• Manufacturing flexibility
• Regulatory response
• Seasonal demand forecasting
• High-risk population targeting
• Distribution planning

The competitive advantage is shifting from simply having a COVID-19 vaccine to having a platform capable of rapidly responding to viral evolution.

Pfizer and BioNTech

Pfizer and BioNTech remain important players in the COVID-19 vaccine ecosystem.

Pfizer’s 2026 pipeline continues to include vaccines as a core area of focus, while the company and BioNTech received U.S. FDA approval for their XFG-adapted COVID-19 vaccine in August 2026.

Pfizer’s May 2026 guidance projected 2026 revenue of $59.5 billion to $62.5 billion, demonstrating the scale of the company beyond COVID-19 alone.

For competitors, investors and suppliers, the important issue is how Pfizer’s vaccine infrastructure is being redeployed toward a broader infectious-disease portfolio.

Moderna

Moderna continues to use its mRNA platform to expand beyond COVID-19.

The company describes a respiratory vaccine portfolio targeting major respiratory viruses and has continued developing mRNA programs across multiple therapeutic areas. Moderna’s current pipeline includes respiratory, infectious-disease and other programs, reinforcing the company’s strategy of using mRNA as a broader vaccine and medicine platform rather than a single-product technology.

For vaccine developers, the strategic question is whether mRNA can deliver commercially viable products across multiple indications while maintaining manufacturing flexibility and acceptable cost structures.

Novavax-Sanofi

The 2026–2027 COVID-19 season also demonstrates the continued relevance of protein-based vaccine technology.

Novavax’s Nuvaxovid remains differentiated from the mRNA products of Pfizer-BioNTech and Moderna, giving the market multiple vaccine technology approaches rather than a single dominant platform.

This technology diversity matters for procurement organizations and governments because vaccine portfolios need resilience against manufacturing, supply, technology and population-specific challenges.

Mpox Is Becoming a Long-Term Vaccine Preparedness Issue

Mpox is another major development shaping vaccine strategy in 2026.

The WHO launched a global initiative in August 2026 to establish a stockpile of mpox vaccines, creating a longer-term mechanism for ensuring countries can access doses during future outbreaks.

This is a major shift in thinking.

Instead of waiting for a large outbreak and then trying to manufacture vaccines, governments and global health organizations are increasingly considering:

Stockpiling → Preparedness → Rapid deployment → Outbreak control

Bavarian Nordic Is a Key Mpox Company to Watch

Bavarian Nordic’s MVA-BN vaccine, marketed as JYNNEOS in the United States, is one of the most important vaccines in the mpox response.

The FDA lists JYNNEOS as a non-replicating smallpox and mpox vaccine manufactured by Bavarian Nordic and indicated for adults at high risk of smallpox or mpox infection.

The company continued receiving government demand in 2026.

In February 2026, Bavarian Nordic announced a US$22.5 million contract with the Government of Canada for MVA-BN.

The company had also entered a larger European framework arrangement covering approximately 1.1 million doses, with 750,000 doses expected to be supplied in 2026.

This creates opportunities beyond vaccine sales.

The mpox value chain includes:

• Vaccine manufacturing
• Government procurement
• Strategic stockpiling
• Cold-chain logistics
• Emergency response
• Regional manufacturing
• Surveillance
• Diagnostic testing
• Public-health planning

For investors and pharmaceutical companies, mpox demonstrates why preparedness contracts and government procurement can become strategically important revenue channels for vaccine manufacturers.

Measles Is the Warning Signal for Routine Immunization

While COVID-19 and mpox attract significant attention, measles may represent one of the most important public-health warning signals in 2026.

Measles is highly contagious, and WHO’s Immunization Agenda 2030 states that approximately 95% coverage with two timely doses of measles-containing vaccine is required to prevent sustained transmission.

Yet vaccination gaps are creating renewed outbreaks.

In the United States, the CDC reported 1,842 confirmed measles cases as of May 7, 2026, compared with 2,289 confirmed cases for the full year of 2025.

The situation is not limited to the United States.

In Bangladesh, WHO reported 19,161 suspected measles cases and 2,973 laboratory-confirmed cases between March 15 and April 14, 2026, along with 30 confirmed measles-related deaths.

These outbreaks highlight a critical issue:

The next vaccine challenge may not always be a new pathogen. It can be a preventable disease returning because vaccination coverage has fallen.

Why Vaccine Coverage Is Becoming a Business and Policy Issue

For vaccine manufacturers, the challenge is no longer only developing effective products.

The industry must also solve:

• Vaccine hesitancy
• Missed childhood vaccinations
• Unequal access
• Procurement delays
• Cold-chain limitations
• Supply shortages
• Public-health communication
• Healthcare workforce capacity
• Regional manufacturing gaps

This creates demand for better intelligence around where vaccination gaps exist, which populations are underserved, and how procurement systems are changing.

Gavi’s 2026–2030 strategy reinforces this broader focus. Gavi supports vaccines against 20 infectious diseases and reports that its programs have helped immunize more than 1.2 billion children since 2000.

The Next Vaccine Opportunity Is Bigger Than COVID-19

The vaccine pipeline is becoming more diversified.

Companies are increasingly investing in vaccines targeting:

RSV

RSV remains an important opportunity because of disease burden among older adults, infants and other vulnerable populations.

Gavi reported in September 2026 that WHO had prequalified a multi-dose RSV maternal vaccine, an important development for protecting infants against severe RSV disease.

Chikungunya

Chikungunya is becoming increasingly important as climate and mosquito distribution change.

Bavarian Nordic CEO Paul Chaplin highlighted the changing epidemiology of mosquito-borne and tick-borne diseases, while the company reported a 415% increase in demand for its chikungunya vaccine Vimkunya in Q2 2026.

TB

Tuberculosis is emerging as another major vaccine opportunity.

Gavi reported in September 2026 that next-generation TB vaccines expected from 2029 could potentially prevent millions of deaths and generate substantial economic benefits.

HPV

HPV vaccination remains a major global cancer-prevention opportunity.

Expanding vaccination coverage in lower-income countries can create significant public-health impact while increasing long-term demand for vaccine procurement and delivery infrastructure.

GSK Shows Why Vaccines Are Becoming a Multi-Platform Business

GSK remains one of the world’s largest vaccine-focused pharmaceutical companies.

The company’s portfolio spans vaccines and medicines across infectious diseases, respiratory disease, oncology, HIV and immunology.

GSK’s 2026 strategy targets reaching 2.5 billion people by the end of the decade, while its infectious-disease portfolio remains a major strategic area.

The lesson for competitors is important:

The future vaccine business will not be built around one blockbuster vaccine.

It will increasingly depend on portfolio breadth, manufacturing scale, technology platforms, geographic reach, procurement relationships and the ability to respond to changing disease patterns.

What Is Changing in Vaccine Manufacturing?

The next phase of vaccine manufacturing is being shaped by flexibility.

Manufacturers need facilities that can respond to:

• New variants
• New pathogens
• Seasonal demand
• Emergency procurement
• Regional outbreaks
• Different vaccine technologies
• Changing regulatory requirements

This is particularly relevant to mRNA and other platform technologies.

The ability to rapidly change antigen design or production parameters can become a competitive advantage.

However, flexibility alone is not enough.

Companies must also consider:

Raw materials → Production capacity → Quality control → Regulatory approval → Cold chain → Distribution → Administration

A bottleneck at any point can limit the commercial or public-health impact of a vaccine.

The Vaccine Supply Chain Is Becoming a Strategic Asset

COVID-19 demonstrated that vaccine manufacturing capacity can become a geopolitical and public-health issue.

In 2026, companies and governments are therefore paying greater attention to:

• Local manufacturing
• Regional supply
• Strategic reserves
• Dual sourcing
• Raw-material availability
• Fill-finish capacity
• Cold-chain infrastructure
• Procurement agreements
• Technology transfer

For vaccine companies, the question is no longer simply:

“How many doses can we manufacture?”

It is:

“How quickly can we produce, approve, distribute and deliver the right vaccine to the right population?”

Who Should Be Watching These Vaccine Trends?

This changing environment creates opportunities and risks for several stakeholder groups.

Pharmaceutical Companies

They need intelligence on:

• Competitor pipelines
• Vaccine approvals
• Clinical trials
• Manufacturing capacity
• Licensing deals
• M&A
• Government procurement
• Regional demand

Biotechnology Companies

Biotech companies need to understand where large pharmaceutical companies are seeking new platforms and partnerships.

Important areas include:

• mRNA
• Viral vectors
• Protein-based vaccines
• Nanoparticle vaccines
• Intranasal vaccines
• Self-amplifying RNA
• Next-generation adjuvants

CDMOs and Manufacturers

The opportunity lies in flexible manufacturing capacity, technology transfer, fill-finish, analytical testing and scalable production.

Governments and Public-Health Agencies

They need visibility into:

• Disease surveillance
• Vaccine coverage
• Procurement
• Stockpiling
• Regional supply
• Outbreak preparedness
• Population-level vaccination gaps

Investors

Investors should evaluate:

• Pipeline maturity
• Technology differentiation
• Manufacturing scalability
• Government contracts
• IP
• Clinical risk
• Market access
• Geographic exposure
• Strategic partnerships

What Could Become the Next Public Health Challenge?

The next major vaccine challenge may not be a single disease.

It could be the combination of:

Emerging pathogens + declining routine vaccination + climate-driven disease expansion + misinformation + supply-chain vulnerability.

This combination makes preparedness much more complicated.

A pathogen does not need to become globally dominant before it creates a commercial and public-health opportunity.

The earlier signals can appear in:

• Localized outbreaks
• Falling vaccination coverage
• New government procurement
• Increased surveillance
• Vaccine stockpiling
• New clinical trials
• Regulatory designations
• Manufacturing investments
• Partnership activity

Companies that identify these signals early can potentially move before the market becomes crowded.

Competitive Intelligence Questions Vaccine Companies Need to Answer

For vaccine manufacturers and investors, the most valuable intelligence increasingly comes from questions such as:

Which vaccine platforms are attracting the most strategic investment?

Which companies are building manufacturing capacity before demand increases?

Which governments are increasing strategic stockpiles?

Where are vaccination coverage gaps creating new procurement opportunities?

Which emerging infectious diseases are receiving increased clinical-development investment?

Which vaccine companies have the strongest late-stage pipelines?

Which technologies can be adapted rapidly to new pathogens?

Where are CDMO partnerships becoming necessary?

Which companies are becoming acquisition or licensing targets?

Which countries are prioritizing local vaccine manufacturing?

These are the questions that move vaccine intelligence from general information toward actual business decisions.

How Towards Healthcare Research & Consulting Can Help

The vaccine landscape is changing too quickly for companies to rely only on annual reports or broad industry forecasts.

Towards Healthcare Research & Consulting can help pharmaceutical, biotechnology, healthcare, investment and public-health organizations convert these developments into actionable intelligence.

Vaccine Market Intelligence

Towards Healthcare can provide:

• Global vaccine market analysis
• Country-level opportunity assessment
• Disease-specific forecasting
• Segment analysis
• Demand assessment
• Growth opportunity mapping
• TAM, SAM and SOM analysis

Competitive Intelligence

Teams can assess:

• Pfizer
• Moderna
• GSK
• Sanofi
• Merck
• AstraZeneca
• Novavax
• Bavarian Nordic
• CSL
• BioNTech
• Emerging biotechnology companies

The analysis can cover:

Pipeline → Clinical trials → Approvals → Manufacturing → Partnerships → M&A → Commercial strategy

Vaccine Pipeline Tracking

Towards Healthcare can monitor:

• Phase I programs
• Phase II programs
• Phase III programs
• Regulatory submissions
• Vaccine approvals
• Trial readouts
• New indications
• Platform technologies
• Competitor launches

Government and Procurement Intelligence

For companies selling vaccines to governments and global-health organizations, intelligence can cover:

• Procurement programs
• Government contracts
• Strategic stockpiles
• Gavi programs
• WHO initiatives
• Regional vaccination campaigns
• Tender opportunities
• Supply requirements

Supply Chain Intelligence

Towards Healthcare can map:

Raw Materials → API/Antigen → Manufacturing → Fill-Finish → Cold Chain → Distribution → Healthcare Provider → Patient

This helps companies identify supply risks, manufacturing partners and expansion opportunities.

Buyer and Partner Intelligence

The analysis can identify potential customers and partners across:

• Pharmaceutical companies
• Biotechnology companies
• Governments
• Public-health agencies
• Hospitals
• Vaccine procurement organizations
• Distributors
• CDMOs
• Research organizations
• Investors

Go-to-Market Strategy

For vaccine companies entering new countries or disease categories, Towards Healthcare can support:

• Market-entry assessment
• Competitor positioning
• Customer segmentation
• Partner identification
• Pricing intelligence
• Distribution analysis
• Regional opportunity mapping
• Launch strategy
• Commercial opportunity assessment

The 2026 Vaccine Landscape Is About Preparedness, Not Just Products

The vaccine industry has entered a more complicated phase.

COVID-19 has become an ongoing variant-management challenge. Mpox is driving the development of long-term stockpiling strategies. Measles is demonstrating the consequences of weakened routine immunization. At the same time, RSV, TB, chikungunya and other diseases are creating new opportunities for vaccine developers.

The companies most likely to benefit will not necessarily be those with the largest vaccine portfolios.

They will be the companies that can combine technology, manufacturing flexibility, supply security, regulatory execution, clinical development and market intelligence.

For pharmaceutical companies, investors, vaccine developers, CDMOs and healthcare organizations, the key question is no longer simply “What is the next vaccine?”

It is:

“Where is the next unmet public-health need developing, and which companies are positioned to respond first?”

Turn Vaccine Trends Into Business Opportunities With Towards Healthcare

Towards Healthcare Research & Consulting helps organizations identify where disease trends, vaccine pipelines, government procurement, manufacturing investment and competitive activity are converging.

Our intelligence can help decision-makers identify:

Emerging opportunities.
High-growth vaccine segments.
Competitor movements.
Pipeline risks.
Manufacturing gaps.
Government procurement opportunities.
Potential partners.
Market-entry opportunities.

If your organization is developing, manufacturing, investing in, supplying or commercializing vaccines, connect with Towards Healthcare Research & Consulting for deeper vaccine intelligence, competitive analysis, pipeline tracking, buyer intelligence and strategic opportunity assessment.

Frequently Asked Questions

What are the major vaccine trends in 2026?

Major trends include updated COVID-19 vaccines, increasing mpox preparedness, measles outbreaks caused by vaccination gaps, expansion of RSV vaccination, next-generation TB vaccines, chikungunya vaccines and broader use of flexible vaccine platforms.

What is happening with COVID-19 vaccines in 2026?

The United States has moved toward updated seasonal vaccines targeting circulating variants. The FDA recommended the JN.1-lineage XFG variant for the 2026–2027 formulation, and updated vaccines from Moderna, Pfizer-BioNTech and Novavax-Sanofi were approved in August 2026.

Why is mpox important for the vaccine industry?

Mpox is increasingly being treated as a long-term preparedness issue. WHO launched a global initiative in August 2026 to establish an mpox vaccine stockpile, while Bavarian Nordic continues to supply MVA-BN to governments.

Why are measles outbreaks increasing?

Measles outbreaks are being driven partly by gaps in routine immunization. WHO states that approximately 95% coverage with two timely measles-containing vaccine doses is required to prevent sustained transmission.

Which companies are important in the global vaccine industry?

Major companies include Pfizer, BioNTech, Moderna, GSK, Sanofi, Merck, AstraZeneca, Novavax, Bavarian Nordic and CSL, alongside numerous biotechnology and specialized vaccine developers.

Which emerging vaccines should companies watch?

RSV, TB, chikungunya, mpox, next-generation COVID-19 vaccines, HPV and vaccines targeting emerging infectious diseases are important areas to monitor.

What opportunities exist for vaccine manufacturers?

Key opportunities include next-generation vaccine platforms, regional manufacturing, government stockpiling, CDMO services, outbreak-response capacity, cold-chain infrastructure and vaccines for diseases with low current coverage.

How can Towards Healthcare support vaccine companies?

Towards Healthcare can support companies with vaccine market intelligence, competitive benchmarking, pipeline tracking, government procurement intelligence, supply-chain analysis, buyer intelligence, partner identification, market-entry strategy and commercial opportunity assessment.